Levant Tinaz - Profound Medical Software Developer
PRN Stock | CAD 10.56 0.12 1.12% |
Insider
Levant Tinaz is Software Developer of Profound Medical Corp
Address | 2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5 |
Phone | 647 476 1350 |
Web | https://www.profoundmedical.com |
Profound Medical Management Efficiency
The company has return on total asset (ROA) of (0.4462) % which means that it has lost $0.4462 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9017) %, meaning that it generated substantial loss on money invested by shareholders. Profound Medical's management efficiency ratios could be used to measure how well Profound Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of December 2024, Return On Tangible Assets is likely to drop to -0.69. In addition to that, Return On Capital Employed is likely to drop to -0.8. At this time, Profound Medical's Total Assets are very stable compared to the past year. As of the 13th of December 2024, Other Assets is likely to grow to about 4.4 M, while Non Current Assets Total are likely to drop about 1.9 M.Similar Executives
Found 10 records | INSIDER Age | ||
Fahar Merchant | Medicenna Therapeutics Corp | 67 | |
JD BA | HLS Therapeutics | 43 | |
BA LLB | HLS Therapeutics | 65 | |
Tim MBA | HLS Therapeutics | 52 | |
Samuel MD | Medicenna Therapeutics Corp | N/A | |
David Spence | HLS Therapeutics | 56 | |
MBBS MD | Medicenna Therapeutics Corp | N/A | |
Sanjiv Sharma | HLS Therapeutics | 68 | |
Gilbert Godin | HLS Therapeutics | 65 | |
Janet CA | Aptose Biosciences | N/A |
Management Performance
Return On Equity | -0.9 | ||||
Return On Asset | -0.45 |
Profound Medical Corp Leadership Team
Elected by the shareholders, the Profound Medical's board of directors comprises two types of representatives: Profound Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Profound. The board's role is to monitor Profound Medical's management team and ensure that shareholders' interests are well served. Profound Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Profound Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Arun MBA, Chairman CEO | ||
Hartmut Warnken, Senior Alliances | ||
Jacques Cornet, Senior Sonalleve | ||
Stephen Kilmer, Investor Relations | ||
Mathieu Burtnyk, Senior TULSAPRO | ||
Thomas MBA, Chief Officer | ||
Abbey Goodman, Chief Global | ||
Levant Tinaz, Software Developer | ||
Michael Mydra, VP Access | ||
Rashed Dewan, Chief Officer |
Profound Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Profound Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.9 | ||||
Return On Asset | -0.45 | ||||
Operating Margin | (3.17) % | ||||
Current Valuation | 291.68 M | ||||
Shares Outstanding | 30.03 M | ||||
Shares Owned By Insiders | 6.90 % | ||||
Shares Owned By Institutions | 35.98 % | ||||
Number Of Shares Shorted | 92.65 K | ||||
Price To Book | 7.30 X | ||||
Price To Sales | 35.76 X |
Pair Trading with Profound Medical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Profound Medical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Profound Medical will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Profound Medical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Profound Medical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Profound Medical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Profound Medical Corp to buy it.
The correlation of Profound Medical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Profound Medical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Profound Medical Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Profound Medical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Profound Medical Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.